Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer Sells 22,468 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 22,468 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at $1,258,340.40. The trade was a 41.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Ian Mortimer also recently made the following trade(s):

• On Monday, January 27th, Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $40.50, for a total value of $660,757.50.

Xenon Pharmaceuticals Stock Up 0.4 %

XENE stock opened at $40.11 on Tuesday. Xenon Pharmaceuticals Inc. has a 52 week low of $35.53 and a 52 week high of $50.99. The company has a market cap of $3.06 billion, a price-to-earnings ratio of -14.22 and a beta of 1.20. The business has a fifty day simple moving average of $40.20 and a 200-day simple moving average of $40.82.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.01. During the same period in the previous year, the company earned ($0.73) earnings per share. As a group, analysts expect that Xenon Pharmaceuticals Inc. will post -3.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 487 shares in the last quarter. Advisors Asset Management Inc. increased its holdings in Xenon Pharmaceuticals by 3.8% in the 3rd quarter. Advisors Asset Management Inc. now owns 13,592 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 493 shares in the last quarter. Blue Trust Inc. raised its position in Xenon Pharmaceuticals by 174.7% in the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 641 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of Xenon Pharmaceuticals by 1.6% during the second quarter. Envestnet Asset Management Inc. now owns 48,946 shares of the biopharmaceutical company’s stock worth $1,908,000 after purchasing an additional 769 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of Xenon Pharmaceuticals by 39.8% in the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 780 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on XENE shares. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Raymond James reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Finally, HC Wainwright reissued a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $56.00.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.